Idiopathic Pulmonary Fibrosis Treatment Market: Presence of a Strong Pipeline

The global idiopathic pulmonary fibrosis treatment market size
is expected to reach a value of USD 5.2 billion by 2026, according to a new
report by Grand View Research, Inc. It is anticipated to register a CAGR of
12.7% during the forecast period. Increasing R&D initiatives undertaken by
companies and surge in cigarette smoking population are anticipated to boost
the growth.
Rise in the initiatives undertaken by manufacturers
to develop products with novel mechanisms is anticipated to fuel the idiopathic
pulmonary fibrosis (IPF) treatment market growth. For instance, FibroGen, Inc.,
is currently developing a drug, pamrevlumab - a monoclonal antibody that
targets the connective tissue growth factor. The phase III trials of
pamrevlumab are expected to be initiated in the first half of 2019. The drug
has received fast track designation from the Food and Drug Administration
(FDA).
An aging population can be expected to have
far-reaching social, economic, and political implications on nearly all the
sectors including the healthcare sector. An associated consequence of an
increase in the geriatric population will be an increase in the incidences of
various medical conditions requiring long-term care. Moreover, the growing
geriatric population base in countries with large untapped opportunities such
as China and Japan is anticipated to drive the market growth during the
forecast period.
The dramatic increase in cigarette smoking
population is one of the major drivers likely to have a positive impact on IPF
treatment market growth. According to the U.S. FDA and Centers for Disease
Control and Prevention (CDC), in 2018, more than 3.6 million high and middle
school students were existing e-cigarette users. The number increased by 1.5
million since the last year. The uptake in the use of e-cigarette is expected
to lead to the incidence of IPF.
Further
key findings from the study suggest:
- MAPK Inhibitors segment held the largest market share in 2018.
Esbriet is the first drug approved for the treatment of IPF
- Tyrosine kinase inhibitor is the second largest segment and is
expected to expand at a CAGR of 11.0%
- Autotaxin inhibitors (GLPG1690) is expected to post lucrative CAGR.
GLPG1690 is currently in phase III trial and is expected to be
commercialized in 2022
- U.S. led in 2018 due to high market penetration and high awareness
pertaining to IPF
- IPF treatment market in Japan is estimated to decline over the
forecast period owing to patent expiry of Esbriet in 2018
- Some of the major players operating in the idiopathic pulmonary fibrosis
treatment market are F. Hoffman La-Roche Ltd; Boehringer Ingelheim
International GmbH; Galapagos; FibroGen, Inc.; Prometic Life Sciences
Inc.; Bristol-Myers Squibb Company; MediciNova, Inc.; Merck & Co.,
Inc.; Novartis AG; and Merck & Co.
Access
full research report on global idiopathic pulmonary fibrosis treatment market:
www.grandviewresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-ipf-treatment-market
Comments